During the last 10 years, we have witnessed success after success for the treatment of advanced melanoma, and data presented at the 2016 American Society of Clinical Oncology (ASCO) annual meeting continued this upward trend. While impressive long-term overall and progression-free survival (PFS) data were presented for patients with advanced melanoma treated with both immune and targeted therapies, sobering data were presented regarding therapy for NRAS-mutant and uveal subtypes, proving that the battle is far from won.
Menzies AM, Long GV. Recent Developments in Melanoma Therapy. JAMA Oncol. 2016;2(10):1259-1260. doi:10.1001/jamaoncol.2016.3418